Home    Back

Reldesemtiv 150 mg    (DrugBank: Reldesemtiv)

2 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis0
3Spinal muscular atrophy1

2. Amyotrophic lateral sclerosis    [ 508 clinical trials,   530 drugs,   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways]
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 508 trial found

3. Spinal muscular atrophy    [ 179 clinical trials,   102 drugs,   (DrugBank: 26 drugs),   52 drug target genes,   78 drug target pathways]
Searched query = "Spinal muscular atrophy", "Myelopathic muscular atrophy", "SMA I", "Werdnig-Hoffman disease", "SMA II", "Dubowitz disease", "SMA III", "Kugelberg-Welander disease", "SMA IV"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 179 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02644668
(ClinicalTrials.gov)		January 14, 201623/12/2015A Study of CK-2127107 in Patients With Spinal Muscular AtrophyA Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study of CK-2127107 in Two Ascending Dose Cohorts of Patients With Spinal Muscular AtrophySpinal Muscular AtrophyDrug: Placebo;Drug: Reldesemtiv 150 mg;Drug: Reldesemtiv 450 mgCytokineticsAstellas Pharma Global Development, Inc.Completed12 YearsN/AAll70Phase 2United States;Canada